FDA Approved Atebrioz for Rare Bone Disorder

The FDA approved a new once-daily oral medication to treat patients 12 and older with fibrodysplasia ossificans progressiva.

Updated on Sept. 25, 2026 in Biotech

Isometric editorial illustration of a complex geometric structure, representing the targeted biological inhibition of protein growth. — The U.S. Food and Drug Administration approved Mirum Pharmaceuticals' Atebrioz for patients 12 and older with the rare genetic condition fibrodysplasia ossificans progressiva. AI Illustration. Upload story photo >

Live Poll

Should the government place stricter limits on how much drug companies can charge for new treatments?

The U.S. Food and Drug Administration approved Mirum Pharmaceuticals' drug Atebrioz for the treatment of fibrodysplasia ossificans progressiva, a rare genetic disorder. The medication is the first of its kind approved for patients 12 years and older.

Why it matters

The approval provides a new treatment option for patients suffering from this debilitating genetic condition, which causes bone to form abnormally within muscles and soft tissues. By blocking the ALK2 protein, the medication targets the underlying biological cause of the disease.

Atebrioz is a once-daily oral treatment administered at a 100-milligram dose for patients aged 12 and older. The drug functions by specifically blocking the ALK2 protein that exhibits abnormal activity in patients with the disorder.

The players

Food and Drug Administration

This federal agency is responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs and medical devices.

Mirum Pharmaceuticals

This is a biopharmaceutical company that focuses on the development and commercialization of novel therapies for rare diseases.

The details

Atebrioz addresses the rare condition known as fibrodysplasia ossificans progressiva, where the body incorrectly forms bone in ligaments, tendons, and muscles. The medication works by inhibiting the ALK2 protein responsible for this pathological bone growth.

September 25, 2026: The FDA officially approved the drug Atebrioz.
October 2026: Mirum Pharmaceuticals plans to launch the drug to the market.

Biotech
Sept. 28
FDA to Issue Decisions on Two Biotech Drugs This Week
Allergies
Sept. 18
FDA Approved Fayuvi for Sanfilippo Syndrome Type A
Cancer
Sept. 21
FDA Conditionally Accepted Name for Lirafugratinib

The Tech Race

This approval signals a major shift toward targeted molecular therapies for rare genetic bone conditions. It builds upon previous research into protein pathway modulation to replace legacy symptom-management approaches in rare disease biotech.

Eligible patients aged 12 and older will soon have access to a new once-daily oral medication to manage their condition. Families should consult their healthcare providers to discuss treatment suitability and upcoming availability in October.

The takeaway

This approval marks a significant milestone for patients living with fibrodysplasia ossificans progressiva by offering a targeted treatment option for the first time. Patients and caregivers should track upcoming October launch updates for information regarding medication access and pricing.

What happens next

Mirum Pharmaceuticals is scheduled to launch Atebrioz in October 2026, at which time the company plans to disclose the official pricing for the medication.